In 2014 researchers conducted a clinical trial with 308 women with a history of recurrent UTIs. Intervention was prophylactic treatment with either 2 g D-mannose powder, or 50 mg of the antibiotic nitrofurantoin, or in the third group no prophylactic treatment at all. There was a significantly greater rate of recurrent UTI in the group …
In 2020 a group of researchers investigated the evidence and validity of D-mannose use as an intervention or prophylactic treatment for recurrent urinary tract infections. Eight publications met eligibility. Relative risk of urinary tract infection recurrence comparing D-mannose to placebo was 0.23 (D-mannose n=125, placebo n=123). Concluding that D-mannose is protective for UTI (versus placebo) …
This meta-analysis from 2012 highlights the importance of the right dose and ratios of myo-inositol and D-chiro-inositol in the effects observed with supplementation. In this randomized, placebo-controlled clinical study, PCOS patients were randomized into one of five groups: a placebo group, and four groups receiving increasing doses of D-chiro-inositol (300, 600, 1200 and 2400 mg) …
In this randomized, controlled trial, researchers aimed to assess the effect of D-chiro-inositol and folic acid supplementation on glucose control and insulin resistance in overweight/obese patients with type I diabetes. DCI and folic acid supplementation led to a significant reduction in HbA1C levels, compared to the control group, suggesting that DCI and folic acid supplementation …
This randomized, placebo-controlled clinical study from 2016 aimed to evaluate the effect of a combination of folic acid, myo-inositol (MI) and D-chiro inositol (DCI) in young overweight women with polycystic ovary syndrome (PCOS), characterized by anovulation and hyperandrogenism, correlated to insulin resistance. Participants received either a placebo or folic acid (200 μg) + MI (550 …
In a double-blind, randomized, placebo-controlled trial from 2014, 928 seniors (703 were female) from long-term care facilities were divided into low-risk and high-risk groups for UTIs. Participants were given either 500 mg cranberry extract or placebo twice daily for 12 months. Those defined as “high-risk”, which included participants with long-term catheterization, diabetes or at least …
In a randomized trial from 2015, 160 patients undergoing elective gynecologic surgery were randomized to receive 720 mg cranberry fruit extract or placebo twice daily for six weeks post-op. The occurrence of UTI was significantly lower in the cranberry group, 19%, compared to 38% in the placebo group. References: Foxman B, Cronenwett AEW, Spino C, …
This randomized, double-blind, placebo-controlled clinical trial was published in 2013. Researchers recruited 84 postmenopausal women to determine the impact of black cohosh supplementation on vasomotor symptoms such as hot flashes over eight weeks. Authors founds that there was a significant difference between the two groups in terms of severity and number of hot flashes in …
In this 2018 comparative randomized, double-blind clinical study, researchers reviewed the efficacy of Cimicifuga racemosa in comparison with evening primrose oil (EPO). 80 postmenopausal women with menopause-related symptoms were assessed. Authors concluded both herbs were effective in reducing the severity of hot flashes and improvement of the quality of life, though black cohosh more significantly …
This systematic review published in 2022 summarized the bioactive constituents, pharmacology, pharmacokinetics, therapeutic potentials, quality control processes, chromatographic techniques, and possible mechanisms of action of clinically effective phytomedicine black cohosh for women’s health. references: Mohapatra S, Iqubal A, Ansari MJ, Jan B, Zahiruddin S, Mirza MA, Ahmad S, Iqbal Z. Benefits of Black Cohosh (Cimicifuga …
